HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPTHY

Clinical trials for HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPTHY explained in plain language.

Never miss a new study

Get alerted when new HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPTHY trials appear

Sign up with your email to follow new studies for HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPTHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New study tracks Real-World safety of hATTR-PN drug TEGSEDI

Knowledge-focused Recruiting now

This study follows 240 adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) to monitor the long-term safety of the drug TEGSEDI. Researchers will compare patients who have taken TEGSEDI with those who have not, focusing on risks like low platelet counts…

Matched conditions: HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPTHY

Sponsor: Akcea Therapeutics • Aim: Knowledge-focused

Last updated May 04, 2026 00:09 UTC

HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPTHY

Get alerted when new HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPTHY trials appear

New study tracks Real-World safety of hATTR-PN drug TEGSEDI